Paul is Vice President of Development Operations at Tevard Biosciences. Since joining the company in 2023, he has managed the advancement of the company’s development portfolio of tRNA-based gene therapies for rare diseases. Paul has more than 30 years of leadership experience in research and development across biotech and large pharmaceutical organizations, spanning multiple therapeutic areas.
Prior to Tevard, Paul was Executive Director of Program Management at CRISPR Therapeutics (NASDAQ: CRSP). Earlier in his career, he held project planning and program management roles at Alzheon, Genzyme Corporation, and Creative BioMolecules, after a joint faculty appointment at Dana-Farber Cancer Institute and Harvard Medical School and a postdoctoral fellowship at the Salk Institute for Biological Studies.
Paul holds a Ph.D. from The University of Texas Southwestern Medical Center, an MBA from Northeastern University, and an A.B. from the University of Pennsylvania.